A Korean research team has developed a new viral vector technology that significantly improves the production efficiency of ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Austin, United States, June 09, 2026 (GLOBE NEWSWIRE) -- "The Viral Vector Production (Research-use) Market was valued at USD 1.95 billion in 2025 and is projected to reach USD 8.26 billion by 2035, ...

Genetic engineering could be used to develop new, more effective production systems for viral vector producing cell lines.

Human embryonic kidney (HEK293) cells are the most commonly used cell line to produce viral vectors for gene therapy. Due to the complexity of their production and purification, viral vectors can be ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a ...

Qualified Vero Master Cell Bank and Working Cell Bank, originating from WHO banks, are available for purchase, licensing, and use in ...